BBIO

74.52

0.05% 0.04

Vorhandelsmarkt: 74.80 0.28 +0.38%

Bridgebio Pharma Inc (BBIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BBIO? Forum Prognose

Schlusskurs vom Vortag:

$74.48

Offen:

$74.48

24-Stunden-Volumen:

3.03M

Relative Volume:

0.99

Marktkapitalisierung:

$14.60B

Einnahmen:

$579.96M

Nettoeinkommen (Verlust:

$-729.89M

KGV:

-19.89

EPS:

-3.7459

Netto-Cashflow:

$-452.02M

1W Leistung:

+7.44%

1M Leistung:

+14.01%

6M Leistung:

-2.58%

1J Leistung:

+74.19%

1-Tages-Spanne:

$73.56

$75.28

1-Wochen-Bereich:

$68.82

$75.28

52-Wochen-Spanne:

$42.09

$84.94

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Firmenname

Bridgebio Pharma Inc

Sektor

Healthcare (1092)

Branche

Biotechnology (615)

Telefon

(650) 391-9740

Adresse

3160 PORTER DR., PALO ALTO, CA

Mitarbeiter

839

Twitter

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

BBIO's Discussions on Twitter

Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BBIO Bridgebio Pharma Inc	74.52	14.59B	579.96M	-729.89M	-452.02M	-3.7459
VRTX Vertex Pharmaceuticals Inc	498.01	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	624.72	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	909.50	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.67	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	187.51	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-09	Eingeleitet	RBC Capital Mkts	Outperform
2026-03-10	Eingeleitet	William Blair	Outperform
2026-01-28	Eingeleitet	Barclays	Overweight
2026-01-06	Eingeleitet	Morgan Stanley	Overweight
2025-12-11	Eingeleitet	Bernstein	Outperform
2025-07-30	Fortgesetzt	Raymond James	Outperform
2025-07-21	Eingeleitet	Truist	Buy
2025-07-14	Eingeleitet	Jefferies	Buy
2025-07-09	Hochstufung	Oppenheimer	Perform → Outperform
2025-06-17	Eingeleitet	Wolfe Research	Outperform
2025-03-31	Eingeleitet	Redburn Atlantic	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-10-03	Eingeleitet	Oppenheimer	Perform
2024-09-04	Eingeleitet	Piper Sandler	Overweight
2024-03-21	Fortgesetzt	Raymond James	Outperform
2024-01-31	Eingeleitet	BMO Capital Markets	Market Perform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-11-07	Eingeleitet	Citigroup	Buy
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-07-18	Herabstufung	Jefferies	Buy → Hold
2023-04-19	Eingeleitet	Evercore ISI	Outperform
2023-02-06	Eingeleitet	Cowen	Outperform
2021-12-27	Bestätigt	Mizuho	Buy
2021-12-27	Bestätigt	SVB Leerink	Outperform
2021-09-10	Hochstufung	BofA Securities	Neutral → Buy
2021-05-21	Eingeleitet	UBS	Buy
2021-03-22	Bestätigt	Goldman	Buy
2021-02-22	Fortgesetzt	JP Morgan	Overweight
2021-02-09	Fortgesetzt	Goldman	Buy
2021-01-11	Bestätigt	H.C. Wainwright	Buy
2020-12-10	Bestätigt	H.C. Wainwright	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Neutral
2020-05-19	Eingeleitet	BTIG Research	Buy
2020-04-13	Eingeleitet	H.C. Wainwright	Buy
2020-02-19	Eingeleitet	Mizuho	Buy
2019-07-26	Eingeleitet	Raymond James	Outperform
2019-07-22	Eingeleitet	BMO Capital Markets	Outperform
2019-07-22	Eingeleitet	Goldman	Buy
2019-07-22	Eingeleitet	JP Morgan	Overweight
2019-07-22	Eingeleitet	Jefferies	Buy
2019-07-22	Eingeleitet	Piper Jaffray	Overweight
2019-07-22	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

01:43 AM

Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026 - Legal Desire Media and Insights

01:43 AM

Jul 01, 2026

BridgeBio lands $1 billion, mostly from S.F.'s Sixth Street, with three late-stage drugs in hand - The Business Journals

Jul 01, 2026

BridgeBio Pharma Announces $1 Billion Convertible Preferred Equity Deal - Moomoo

Jul 01, 2026

BridgeBio raises $1 billion in preferred equity - The Pharma Letter

Jul 01, 2026

BridgeBio secures up to $1B in preferred equity - MSN

Jul 01, 2026

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches - Sixth Street

Jul 01, 2026

BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street - MSN

Jul 01, 2026

BridgeBio secures $1 billion in convertible preferred equity - Investing.com

Jul 01, 2026

BridgeBio gets $1B from Sixth Street, HCRx for three launches - Stock Titan

Jul 01, 2026

Global private equity giants continue to increase investments in the innovative pharmaceuticals sector, with firms including KKR injecting $1 billion into BridgeBio. - Moomoo

Jul 01, 2026

Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity - 富途牛牛

Jul 01, 2026

Jun 30, 2026

Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity - Bloomberg.com

Jun 30, 2026

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance

Jun 30, 2026

Jun 29, 2026

BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Index - marketscreener.com

Jun 29, 2026

BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO) - Seeking Alpha

Jun 29, 2026

BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Value Benchmark - marketscreener.com

Jun 29, 2026

BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Growth Benchmark - marketscreener.com

Jun 29, 2026

Sector Update: Healthcare - Moomoo

Jun 29, 2026

BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial - Moomoo

Jun 29, 2026